Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 20/20 | 1.00 |
| ▸ | F13A1 | P00488 | 17/20 | 1.00 |
| ▸ | TGM1 | P22735 | 14/20 | 1.00 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1871356 | 0.89 | TGM2 (1.00) | TGM2F13A1TGM1TGM3 | |
| SCHEMBL1874385 | 0.89 | TGM2 (1.00) | TGM2F13A1TGM1TGM3 | |
| SCHEMBL1872590 | 0.87 | TGM2 (1.00) | TGM2F13A1TGM1TGM3 | |
| SCHEMBL1869819 | 0.84 | TGM2 (1.00) | TGM2F13A1TGM1TGM3 | |
| SCHEMBL1867871 | 0.84 | TGM2 (0.79) | TGM2F13A1TGM1TGM3 | |
| SCHEMBL14490316 | 0.81 | TGM2 (0.67) | TGM2F13A1TGM1TGM3 | |
| SCHEMBL18763033 | 0.79 | TGM2 (0.65) | TGM2F13A1TGM1TGM3 | |
| SCHEMBL5442111 | 0.79 | TGM2 (0.64) | TGM2F13A1TGM1TGM3 | |
| SCHEMBL14490212 | 0.79 | TGM2 (0.64) | TGM2F13A1TGM1TGM3 | |
| SCHEMBL14915727 | 0.78 | TGM2 (0.72) | TGM2F13A1TGM1TGM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946197-B2 | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2015-02-03 | — | — | US | claimed |
| US-8946197-B2 | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946197-B2 | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130116216-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | EVOTEC (UK) LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| US-20130116216-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | EVOTEC (UK) LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| WO-2011060321-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116216-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | HTT, TGM2, GRN | TGM2 2/4885F13A1 1540/4885TGM1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.